실험실 자동화 소프트웨어 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the lab automation software market size is projected to be USD 6.30 billion in 2025, USD 6.82 billion in 2026, and reach USD 9.65 billion by 2031, growing at a CAGR of 7.19% from 2026 to 2031.

This report is Segmented by Software (LIMS, LIS, CDS, ELN, SDMS, and Integrated Platforms), Deployment Model (On-Premise, Cloud-Based, and Hybrid), End User (Pharma and Biotech, Cros, Clinical Diagnostics, Academic Institutes, and More), Field of Application (Drug Discovery, Genomics, Proteomics, Clinical Diagnostics, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Lab Automation Software Market Trends and Insights

Accelerated AI-Driven Workflow Optimization

Generative AI now schedules instrument runs, predicts reagent depletion, and flags anomalous peaks before human review, cutting repetitive tasks and improving first-pass yield. Thermo Fisher Scientific integrated large language models across its Unity Lab Services platform in January 2026, allowing researchers to issue natural-language queries and receive protocol recommendations in seconds. Early adopters report protocol-development cycles shrinking by 60% during 2025 beta programs. Ginkgo Bioworks scaled autonomous foundries that iterate strain designs without manual intervention, showing the model's viability beyond pharmaceuticals. Mid-term benefit peaks once labs validate AI-generated methods under ISO 17025 and CLIA, though definitive regulatory guidance remains forthcoming.

Rising Adoption of Cloud-Native LIMS Platforms

Separating compute from storage lets labs scale resources during heavy sequencing runs and idle them during lulls. A December 2025 TetraScience survey found 68% of biopharma quality-control labs planning at least one cloud migration by end-2026, citing disaster recovery and remote access as top drivers. Kubernetes-orchestrated microservices, introduced in LabVantage LIMS v8.7, enable automated failovers with sub-second queries across multi-terabyte datasets. CROs with global footprints see immediate ROI, as ICON plc reduced cross-site data reconciliation by 40% after deploying cloud-based sample tracking. Sovereign data laws in China and Russia still compel hybrid topologies, creating nuanced architecture decisions.

Shortage of Domain-Savvy Automation Engineers

BioSpace reported 73% of U.S. biopharma firms unable to fill automation-engineer roles within 120 days during 2025, extending project timelines. Skills must span assay protocols, API design, and regulatory statutes such as GAMP 5, creating rare hybrid profiles. Tecan Group launched an internal academy to cross-train technicians in Python scripting and robotic-arm programming. Universities offer limited laboratory-informatics coursework, forcing companies to fund six-to-twelve-month upskilling, slowing near-term software rollouts.

Other drivers and restraints analyzed in the detailed report include:

1. Pharma Outsourcing Surge in Emerging Markets
2. Convergence of Multi-omics and Automation
3. Data-Security Concerns in Public Cloud Deployments

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Laboratory Information Management Systems accounted for 43.00% of 2025 revenue, anchoring the lab automation software market with validated batch-release workflows in regulated pharma quality-control environments. Cloud-native variants are forecast to expand at a 13.40% CAGR, propelled by CRO demand for elastic capacity and pay-per-sample economics. Electronic lab notebooks and scientific data management systems are converging into unified subscription bundles, as Thermo Fisher's AI-enriched Unity platform bundles LIMS, ELN, and middleware for one fee. Chromatography data systems remain entrenched, but Waters embedded core CDS functions directly into Arc HPLC firmware to lower standalone license costs. Integrated platforms from ABB and Mettler Toledo link benchtop robotics to enterprise analytics, signaling a shift toward holistic orchestration. These developments create a competitive gradient where established vendors rely on regulatory pedigrees while API-first entrants court cost-sensitive labs. The lab automation software market size for integrated platforms is expected to expand steadily, given their double-digit CAGR and growing preference among multi-omics programs.

Legacy LIS environments in diagnostics are gradually merging with LIMS as molecular pathology blurs research and clinical domains; Roche's cobas pro automates sample flow from accessioning to report, exemplifying this overlap. Benchling's ELN advanced version-control features attracted cross-functional discovery teams, especially where fine-grained audit trails are vital. Dotmatics' machine-learning classifiers auto-tag unstructured datasets, improving knowledge capture in large pharmas. ISO 17025 and CLIA validation continues to favor incumbents with long audit histories, yet pre-validated connectors from startups are eroding traditional switching costs.

Cloud deployments held 51.20% revenue in 2025 and are projected to climb at a 15.20% CAGR, marking the fastest shift inside the lab automation software market. Subscription models convert hardware outlays to operational expense, and lab teams rely on built-in redundancy instead of on-premise server rooms. Kubernetes-ready releases such as LabVantage v8.7 illustrate container portability across AWS, Azure, or private data centers. Hybrid topologies, which replicate metadata to the cloud while retaining raw instrument files locally, appeal to jurisdictions enforcing strict data-residency rules. However, data-egress fees emerge as hidden costs; Oxford Nanopore mitigates these by performing edge base calling. The lab automation software market share for on-premise deployments remains sticky in defense and agrochemical labs bound by export-control mandates, yet overall momentum favors cloud incremental migrations.

Rapid cloud validation is another catalyst. Providers now supply pre-qualified instances with 21 CFR Part 11 controls, cutting validation from months to weeks. Nevertheless, the 2025 ransomware breach in Europe forced many labs to require SOC 2 Type II reports and third-party penetration audits before contract signature, elongating sales cycles. Over the forecast period, workload portability and unit-based pricing will tilt even cautious enterprises toward cloud-heavy hybrids.

Complete Report Scope:

• By Software
  • Laboratory Information Management System (LIMS)
  • Laboratory Information System (LIS)
  • Chromatography Data System (CDS)
  • Electronic Lab Notebook (ELN)
  • Scientific Data Management System (SDMS)
  • Integrated Automation Platforms
• By Deployment Model
  • On-Premise
  • Cloud-Based
  • Hybrid
• By End User
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Clinical Diagnostics Laboratories
  • Academic and Research Institutes
  • Other End Users
• By Field of Application
  • Drug Discovery
  • Genomics
  • Proteomics
  • Clinical Diagnostics
  • Other Field of Applications
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Middle East
    • Saudi Arabia
    • United Arab Emirates
    • Rest of Middle East
  • Africa
    • South Africa
    • Rest of Africa

Geography Analysis

North America held 34.00% of market revenue in 2025, supported by dense biopharma clusters in Boston, San Francisco, and Raleigh. The FDA's 2025 21 CFR Part 11 update clarified cloud-signature expectations, prompting many legacy LIMS migrations to AWS and Azure. Canada's National Research Council awarded CAD 50 million (USD 37 million) in grants to help small laboratories automate cleantech and ag-genomics workflows, expanding addressable demand. Mexico's contract-manufacturing hubs have adopted cloud-based LIMS to meet FDA export audit requirements, though rural connectivity gaps still necessitate hybrid installations.

Asia-Pacific is forecast to post a 12.60% CAGR during 2026-2031, the fastest worldwide. China's National Medical Products Administration certified domestic LIMS vendors with Mandarin interfaces, easing validation for local labs. India's USD 1.8 billion in FDI inflows into biopharma automation in 2025 reflects policy incentives and a large STEM talent pool. South Korea earmarked KRW 120 billion (USD 90 million) to digitize public health labs, while Japan is pushing clinical automation to manage an aging population. Australia's draft software-as-medical-device guidance in 2025 opens regulatory pathways for cloud LIMS in diagnostics.

Europe's outlook is tied to the EU Clinical Trials Regulation, which mandates electronic source-data capture; Germany's Annex 11 update in 2024 further clarified cloud validation standards, unlocking migrations among Bavarian manufacturers. The United Kingdom now runs a divergent post-Brexit regime, forcing dual-compliant systems among pan-European labs. France allocated EUR 40 million (USD 45 million) to academic automation grants, and Spain's Catalonia region issued tax credits for AI-enabled bioprocessing. In the Middle East, Saudi Vision 2030 earmarked SAR 2 billion (USD 533 million) for genomics labs that must support Arabic-language LIMS reporting. Africa remains early stage; South Africa's National Health Laboratory Service piloted cloud chromatography data systems to centralize HIV testing across provinces.

1. Thermo Fisher Scientific Inc.
2. Danaher Corporation
3. Becton, Dickinson and Company
4. Agilent Technologies Inc.
5. Siemens Healthineers AG
6. Tecan Group Ltd.
7. PerkinElmer Inc.
8. Bio-Rad Laboratories Inc.
9. Roche Holding AG
10. Eppendorf AG
11. Shimadzu Corporation
12. Waters Corporation
13. LabVantage Solutions Inc.
14. Autoscribe Informatics
15. Hudson Robotics Inc.
16. Synchron Lab Automation
17. LabWare Inc.
18. Abbott Laboratories
19. Illumina Inc.
20. Qiagen N.V.
21. Hamilton Company

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Accelerated AI-Driven Workflow Optimisation
  • 4.2.2 Rising Adoption of Cloud-Native LIMS Platforms
  • 4.2.3 Pharma Outsourcing Surge in Emerging Markets
  • 4.2.4 Regulatory Push for Data Integrity (21 CFR Part 11)
  • 4.2.5 Convergence of Multi-omics and Automation
  • 4.2.6 ESG-Linked Funding for Green Laboratories
• 4.3 Market Restraints
  • 4.3.1 Shortage of Domain-Savvy Automation Engineers
  • 4.3.2 Data-Security Concerns in Public Cloud Deployments
  • 4.3.3 High Validation Costs for Regulated Labs
  • 4.3.4 Legacy System Incompatibility with Modern APIs
• 4.4 Industry Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Impact of Macroeconomic Factors on the Market
• 4.8 Porter's Five Forces Analysis
  • 4.8.1 Bargaining Power of Suppliers
  • 4.8.2 Bargaining Power of Buyers
  • 4.8.3 Threat of New Entrants
  • 4.8.4 Threat of Substitute Products
  • 4.8.5 Intensity of Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE)

• 5.1 By Software
  • 5.1.1 Laboratory Information Management System (LIMS)
  • 5.1.2 Laboratory Information System (LIS)
  • 5.1.3 Chromatography Data System (CDS)
  • 5.1.4 Electronic Lab Notebook (ELN)
  • 5.1.5 Scientific Data Management System (SDMS)
  • 5.1.6 Integrated Automation Platforms
• 5.2 By Deployment Model
  • 5.2.1 On-Premise
  • 5.2.2 Cloud-Based
  • 5.2.3 Hybrid
• 5.3 By End User
  • 5.3.1 Pharmaceutical and Biotechnology Companies
  • 5.3.2 Contract Research Organizations
  • 5.3.3 Clinical Diagnostics Laboratories
  • 5.3.4 Academic and Research Institutes
  • 5.3.5 Other End Users
• 5.4 By Field of Application
  • 5.4.1 Drug Discovery
  • 5.4.2 Genomics
  • 5.4.3 Proteomics
  • 5.4.4 Clinical Diagnostics
  • 5.4.5 Other Field of Applications
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 South America
    • 5.5.2.1 Brazil
    • 5.5.2.2 Argentina
    • 5.5.2.3 Rest of South America
  • 5.5.3 Europe
    • 5.5.3.1 Germany
    • 5.5.3.2 United Kingdom
    • 5.5.3.3 France
    • 5.5.3.4 Italy
    • 5.5.3.5 Spain
    • 5.5.3.6 Rest of Europe
  • 5.5.4 Asia-Pacific
    • 5.5.4.1 China
    • 5.5.4.2 Japan
    • 5.5.4.3 India
    • 5.5.4.4 South Korea
    • 5.5.4.5 Rest of Asia-Pacific
  • 5.5.5 Middle East
    • 5.5.5.1 Saudi Arabia
    • 5.5.5.2 United Arab Emirates
    • 5.5.5.3 Rest of Middle East
  • 5.5.6 Africa
    • 5.5.6.1 South Africa
    • 5.5.6.2 Rest of Africa

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.4.1 Thermo Fisher Scientific Inc.
  • 6.4.2 Danaher Corporation
  • 6.4.3 Becton, Dickinson and Company
  • 6.4.4 Agilent Technologies Inc.
  • 6.4.5 Siemens Healthineers AG
  • 6.4.6 Tecan Group Ltd.
  • 6.4.7 PerkinElmer Inc.
  • 6.4.8 Bio-Rad Laboratories Inc.
  • 6.4.9 Roche Holding AG
  • 6.4.10 Eppendorf AG
  • 6.4.11 Shimadzu Corporation
  • 6.4.12 Waters Corporation
  • 6.4.13 LabVantage Solutions Inc.
  • 6.4.14 Autoscribe Informatics
  • 6.4.15 Hudson Robotics Inc.
  • 6.4.16 Synchron Lab Automation
  • 6.4.17 LabWare Inc.
  • 6.4.18 Abbott Laboratories
  • 6.4.19 Illumina Inc.
  • 6.4.20 Qiagen N.V.
  • 6.4.21 Hamilton Company

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment